BioDlink International Company Limited (HKG:1875)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.600
+0.130 (3.75%)
Jul 10, 2026, 9:30 AM HKT
Market Cap2.68B +88.6%
Revenue (ttm)831.99M -31.9%
Net Income-111.69M
EPS-0.15
Shares Out 772.79M
PE Ration/a
Forward PE317.28
Dividendn/a
Ex-Dividend Daten/a
Volume400
Open3.600
Previous Close3.470
Day's Range3.600 - 3.600
52-Week Range1.700 - 5.870
Beta-0.12
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About HKG:1875

BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer; advanced, metastatic or recurrent non-small cell lung cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer; fallopian tube cancer or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatmen... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 613
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1875
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements